We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+48.57%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
+$490M
Cap. Flow
+$115M
Cap. Flow %
4.94%
Top 10 Hldgs %
54.22%
Holding
73
New
11
Increased
23
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$72.8M
2
AZN icon
AstraZeneca
AZN
+$70.9M
3
LLY icon
Eli Lilly
LLY
+$59M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$56.9M
5
ABBV icon
AbbVie
ABBV
+$38M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$139M
2
BSX icon
Boston Scientific
BSX
+$55.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$53.2M
4
ROIV icon
Roivant Sciences
ROIV
+$47.6M
5
DXCM icon
DexCom
DXCM
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$47.6B
$355M 15.31%
1,550,280
– –
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$15.7B
$163M 7.04%
959,860
+371,032
+63% +$56.9M
AZN icon
3
AstraZeneca
AZN
$243B
$150M 6.47%
816,167
+404,200
+98% +$70.9M
VERA icon
4
Vera Therapeutics
VERA
$2.43B
$141M 6.1%
2,793,987
– –
BMY icon
5
Bristol-Myers Squibb
BMY
$132B
$81.6M 3.52%
+1,512,994
New +$72.8M
UTHR icon
6
United Therapeutics
UTHR
$21.7B
$76.8M 3.31%
157,641
-32,985
-17% -$15.4M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$132B
$74.6M 3.22%
164,594
+46,719
+40% +$20.1M
ABBV icon
8
AbbVie
ABBV
$443B
$72.6M 3.13%
317,783
+166,817
+110% +$38M
ISRG icon
9
Intuitive Surgical
ISRG
$125B
$71.9M 3.1%
126,968
+16,072
+14% +$8.56M
COGT icon
10
Cogent Biosciences
COGT
$5.93B
$70.1M 3.02%
1,973,625
-154,316
-7% -$4.34M
LLY icon
11
Eli Lilly
LLY
$1T
$66.3M 2.86%
+61,652
New +$59M
RAPP
12
Rapport Therapeutics
RAPP
$2.11B
$57.8M 2.49%
1,904,408
-43,171
-2% -$1.19M
BBIO icon
13
BridgeBio Pharma
BBIO
$14.9B
$55.1M 2.38%
720,448
-111,399
-13% -$7.31M
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$53.7M 2.32%
745,116
-130,809
-15% -$8.45M
DYN icon
15
Dyne Therapeutics
DYN
$3.58B
$44.1M 1.9%
2,254,161
+1,268,333
+129% +$24M
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$12.5B
$41.4M 1.79%
+697,133
New +$38M
APGE
17
DELISTED
Apogee Therapeutics
APGE
$40.4M 1.74%
534,845
-30,572
-5% -$1.93M
CDTX
18
DELISTED
Cidara Therapeutics
CDTX
$39.8M 1.72%
180,265
+126,068
+233% +$20.4M
PRAX icon
19
Praxis Precision Medicines
PRAX
$9.64B
$37.1M 1.6%
125,722
-47,111
-27% -$8.77M
IMTX icon
20
Immatics
IMTX
$1.39B
$36.1M 1.56%
3,435,542
+1,207,705
+54% +$12.2M
INBX icon
21
Inhibrx
INBX
$1.66B
$35.9M 1.55%
454,657
+14,565
+3% +$992K
IMNM icon
22
Immunome
IMNM
$2.97B
$34.8M 1.5%
1,618,477
+1,182,426
+271% +$20.8M
AVBP icon
23
ArriVent BioPharma
AVBP
$1.47B
$34.1M 1.47%
1,696,752
– –
GKOS icon
24
Glaukos
GKOS
$10.6B
$32.5M 1.4%
288,128
-24,866
-8% -$2.38M
IDYA icon
25
IDEAYA Biosciences
IDYA
$3.7B
$30.6M 1.32%
885,121
-37,574
-4% -$1.2M
1
2 3

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q4 2025 Portfolio in Review

As of Q4 2025, Sofinnova Investments held 73 positions worth $2.32B, up 27% from $1.83B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sofinnova Investments deployed $115M of net new capital in Q4 2025, opening 11 new positions and adding to 23 existing holdings. Its largest new stake was Bristol-Myers Squibb: 1,512,994 shares worth $81.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 89% a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $53.2M trimmed.

  • Sofinnova Investments's largest Q4 2025 buy was Bristol-Myers Squibb: 1,512,994 shares worth $81.6M.
  • Sofinnova Investments added most to AstraZeneca in Q4 2025, an estimated $70.9M increase.
  • Sofinnova Investments's biggest Q4 2025 reduction was Axsome Therapeutics, cutting an estimated $53.2M.
  • Sofinnova Investments fully exited Gilead Sciences in Q4 2025, selling an estimated $139M.
  • Sofinnova Investments's ten largest holdings make up 54% of its $2.32B portfolio in Q4 2025.
  • Sofinnova Investments opened 11 new positions and closed 13 in Q4 2025.
  • Sofinnova Investments's portfolio value rose 27% quarter-over-quarter to $2.32B.

Based on Sofinnova Investments's 13F filing for Q4 2025, filed 13 Feb 2026.